Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date

(2017) Francesca Cinti et al.   Drug Design Development and Therapy

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review

(2016) Sanjay Kalra et al.   ADVANCES IN THERAPY

Erratum. Classification and diagnosis of diabetes. Sec. 2. In Standards of Medical Care in Diabetes – 2016 . Diabetes Care 2016;39(Suppl. 1):S13–S22

(2016)   DIABETES CARE

SGLT2 Inhibitors and the Diabetic Kidney

(2016) Paola Fioretto et al.   DIABETES CARE

8. Pharmacologic Approaches to Glycemic Treatment

(2016)   DIABETES CARE

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes

(2015) Andrew Lewin et al.   DIABETES CARE

Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension

(2015) N. B. Amin et al.   DIABETES OBESITY & METABOLISM

Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin

(2015) N. B. Amin et al.   DIABETES OBESITY & METABOLISM

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

(2014) André J. Scheen   DRUGS

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

(2014) Aurora Merovci et al.   JOURNAL OF CLINICAL INVESTIGATION

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

Pharmacologic Management of Type 2 Diabetes

(2013) William Harper et al.   Canadian Journal of Diabetes

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

(2013) David Z.I. Cherney et al.   CIRCULATION

Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people

(2013) K. Khunti et al.   DIABETES CARE

Achievement of Goals in U.S. Diabetes Care, 1999–2010

(2013) Mohammed K. Ali et al.   NEW ENGLAND JOURNAL OF MEDICINE

Executive Summary: Standards of Medical Care in Diabetes--2012

(2011)   DIABETES CARE

Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy

(2011) A. Z. Fu et al.   DIABETES OBESITY & METABOLISM

A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents

(2011) L. Olansky et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

(2008) Itamar Raz et al.   CURRENT MEDICAL RESEARCH AND OPINION

Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials

(2008) Avraham Karasik et al.   CURRENT MEDICAL RESEARCH AND OPINION